Amgen 10-Kyear ended 2025-12-31

Executive Summary

Amgen delivered 10% revenue growth in FY2025 as higher product volume and newer therapies outweighed falling net prices and weakness in ENBREL. Operating income improved, but the much larger rise in GAAP net income also benefited from investment gains, while operating cash flow declined on working-capital timing. The investment case increasingly rests on Repatha, newer products and a heavily funded late-stage pipeline replacing revenue exposed to biosimilars and Medicare price setting. Investors should weigh those opportunities against substantial debt, a potentially costly tax dispute and near-term regulatory uncertainty around TAVNEOS.

Key Financial Highlights

• Sales drivers: Volume rose 13%, offset by a 3% net-selling-price decline. Repatha grew 36% to $3.02B and TEZSPIRE grew 52% to $1.48B; ENBREL fell 33% to $2.23B, primarily on lower net prices.
• Earnings quality: Other income rose to $2.65B from $506M, largely reflecting unrealized equity-investment gains, primarily on BeOne. The $1.2B Otezla intangible-asset impairment worked in the opposite direction; neither reflects underlying product-volume growth.
• Investment and cash conversion: R&D rose 22% to $7.27B, with later-stage clinical spending rising to $4.28B from $2.83B. OCF fell from $11.5B mainly because of working-capital timing; FY2025 capital expenditures were $1.9B.
• Capital returns: Dividends paid totaled $5.1B. There were no share repurchases, while diluted weighted-average shares were broadly flat at 542M; the $6.8B remaining repurchase authorization did not reduce the share count in FY2025.
• Revenue deductions: Sales deductions reached 54% of gross product sales, up from 52%, underscoring how rebates, discounts and product mix can constrain growth in realized prices.

Business Developments

Amgen is shifting its growth mix toward products with expanding indications and newer launches while investing heavily in replacement revenue. Repatha received a broader U.S. cardiovascular indication; UPLIZNA gained two U.S. approvals, TEZSPIRE gained a new indication, and IMDELLTRA received full U.S. approval after a survival benefit in Phase 3. PAVBLU, UPLIZNA and IMDELLTRA contributed to growth in other product sales, although some comparisons benefit from launches or limited prior-year sales.

Management is committing resources to MariTide: six Phase 3 studies span weight management and related conditions, supported by Phase 2 maintenance findings. This creates a potentially significant new market opportunity, not an approved revenue stream. Amgen also declined to pursue bemarituzumab approval based on Phase 3 data, illustrating pipeline attrition.

Capacity spending supports the broader portfolio: Amgen opened a North Carolina drug-substance facility, subject to regulatory approval for production, broke ground on a second, and announced Ohio and Puerto Rico expansions. Separately, its planned direct-to-patient expansion responds to U.S. pricing-policy pressure; the effect on sales and profitability remains uncertain.

Risk Assessment

• Pricing and reimbursement: Medicare-set prices took effect for ENBREL on 01/01/2026 and are scheduled for Otezla on 01/01/2027; payer leverage, 340B growth and other policy proposals could further reduce realized prices.
• Biosimilar erosion: Multiple Prolia and XGEVA biosimilars launched after 2025 patent expirations, and Amgen expects faster sales erosion in 2026 as newer products must replace established revenue.
• Tax litigation: The Internal Revenue Service seeks $3.6B plus interest for 2010–2012 and $5.1B plus interest and $2.0B in penalties for 2013–2015; Amgen disputes the claims, but eventual payments could substantially exceed accruals.
• Clinical and regulatory execution: In January 2026, the Food and Drug Administration requested voluntary withdrawal of TAVNEOS over trial-endpoint and liver-safety concerns; Amgen disputes the need for withdrawal, leaving its commercial outlook uncertain.
• Debt and financing: Total debt of $54.6B leaves interest expense and refinancing capacity consequential even after 2025 deleveraging; net interest expense was $2.76B.
• Supply and customer concentration: Puerto Rico produces a substantial majority of commercial manufacturing, several inputs have single sources, and three wholesalers accounted for 77% of worldwide gross revenues; disruption could interrupt shipments or sales.
• Asset valuation: Otezla’s impairment demonstrates how changed commercial expectations can produce material charges, while equity-investment fair-value movements can make reported earnings volatile.

Strategic Outlook and Investor Actionables

Amgen enters 2026 with growing products and an ambitious pipeline, but its transition is occurring alongside accelerating biosimilar competition, mandated price reductions and elevated manufacturing investment. The key investor question is whether replacement-product volume and eventual pipeline returns can outrun erosion in the established portfolio without weakening cash available for debt reduction and dividends.

• Monitor product mix: Repatha and newer-product sales growth vs Prolia, XGEVA and ENBREL erosion; sustained aggregate product-sales growth would support the transition thesis.
• Monitor pipeline and regulation: MariTide Phase 3 progress and the TAVNEOS outcome; delays, safety issues or restricted access would weaken expected replacement growth.
• Monitor cash and liabilities: OCF and FCF vs capital spending, debt reduction and developments in the Puerto Rico tax case; deterioration would narrow financial flexibility.